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Abstract
Altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been demonstrated in patients with
treatment-resistant depression, although studies have often conflated patients with unipolar and bipolar depression.
This is problematic given that the two groups often present with opposed neurovegetative symptom patterns. The
aim of this study was to test, for the first time, whether post-awakening cortisol, a highly reliable, naturalistic measure
of HPA functioning, could distinguish patients with clearly defined treatment-resistant unipolar (TRUD) and bipolar
depression (TRBD). A total of 37 patients with TRUD, 17 patients with TRBD, and 47 healthy controls were recruited.
Areas under the curve (AUC) with respect to the ground (g) and increase (i) of post-awakening cortisol concentrations
(awakening, +15, +30, +45, +60, +90 min) were measured over two days. Patients with TRUD had higher total
cortisol production in the morning hours compared to controls (AUCg, p= 0.01), while they did not differ in terms of
the awakening response (AUCi, p= 0.28). By contrast, subjects with TRBD had lower total cortisol when compared to
controls by trend (AUCg, p= 0.07), while they did not differ in the awakening response (AUCi, p= 0.15). A direct
comparison of TRUD and TRBD revealed differences in the AUCg (p= 0.003) and AUCi (p= 0.03). This finding of
comparatively elevated HPA axis activity in the morning in TRUD and attenuated HPA axis activity in TRBD attests to a
fundamental biological distinction between unipolar and bipolar depression. It has implications for the understanding
and treatment of bipolar depression and in differentiating the two types of depression.
Introduction
Depression is a debilitating condition, with a course that
is often recurrent or chronic with a negative impact on
both society and the individual1. Its high prevalence and
the associated functional impairment make depression a
major cause of disease burden around the world2; due to
its longer duration and severity, treatment-resistant
depression significantly contributes to the above burden3.
Although there has been extensive research into the link
between hypothalamic-pituitary-adrenal (HPA) axis
abnormalities and unipolar depression, with findings such
as elevated basal cortisol levels, non-suppression of cor-
tisol following dexamethasone administration, and
alterations in the cortisol awakening response4,5, research
looking into depressive episodes occurring as part of
bipolar disorder—bipolar depression—has been much less
extensive6. This is especially true regarding post-
awakening cortisol concentrations, with only three pub-
lished studies comparing patients with bipolar depression
to healthy controls, two reporting null-findings7,8 and one
reporting higher levels in patients9.
Matters are complicated further by the likelihood that in
some studies, investigators have combined individuals with
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unipolar and bipolar depression within one illness group,
thus confounding results and masking any potential differ-
ences between these two forms of depression. Certain clin-
ical features, such as hypersomnia, diminished energy levels,
diurnal mood variation, psychosis, excessive self-reproach,
and low libido are more common in bipolar rather than
unipolar depression10. Interestingly, several of these char-
acteristics are also encountered in atypical depression,
which is characterised by reversed neurovegetative symp-
toms and seems to exhibit a different endocrine profile
compared to melancholic depression, namely hypocortiso-
lemia as opposed to hypercortisolemia11.
In addition to this diagnostic issue, very few studies to
date have differentiated or attempted to measure the
above biological parameters in clearly defined treatment-
resistant affective disorders. Studies in unipolar depres-
sion have suggested that hypercortisolemia is a factor
associated with treatment resistance12–14, but to date,
there have been no studies in treatment-resistant bipolar
depression.
One of the most relevant HPA axis indices is post-
awakening cortisol concentrations, including the so-
called cortisol awakening response (CAR). Although its
function still remains unclear, perhaps relating to the
anticipation of the demands of the day ahead15, the CAR
has been extensively used as a measure of HPA axis
reactivity to a natural challenge16. However, despite
offering a highly reliable, naturalistic way of assessing
both HPA axis activity and reactivity, post-awakening
cortisol levels have only been measured once in a clearly
defined population of treatment-resistant depression17,
showing no abnormalities when compared to matched
healthy controls. Notably, in this study the focus was on
‘major depressive episodes’, hence there was no explicit
distinction between treatment resistant unipolar (TRUD)
and bipolar depression (TRBD).
The purpose of the present study was therefore to
investigate HPA axis functioning in treatment-resistant
depression, and specifically to compare unipolar and
bipolar depression, using post-awakening cortisol con-
centrations, including the CAR.
Methods and materials
Participants
Recruitment of participants aged 18–75 with TRUD and
TRBD was undertaken through the National Affective
Disorders Services, at the South London and Maudsley
(SLAM) NHS Foundation Trust, a tertiary care service for
treatment-resistant affective disorders. Patients were
predominantly current or previous inpatients in the ser-
vice, with a minority recruited exclusively from the out-
patient service (notably, the two patient groups did not
differ in terms of inpatient vs. outpatient status). All
patients met the criteria for a current depressive episode
using the 10th edition of the International Classification
of Diseases (ICD-10). Patients were included in the uni-
polar depression group if they met criteria for recurrent
depressive disorder or a single depressive episode, and
into the bipolar depression group if they met criteria for
bipolar affective disorder, currently depressed. Diagnoses
were made by consensus following a longitudinal psy-
chiatric assessment by at least two psychiatrists supple-
mented by the Mini International Neuropsychiatric
Interview18. The 21 item version of the Hamilton Rating
Scale for Depression (HAMD 21) was used to assess the
severity of the current depressive episode19. Only patients
with a score of at least 17 points were included. To define
treatment resistance, patients needed as a minimum to
have failed to respond to at least two classes of anti-
depressants at the minimum therapeutic dose and
duration20,21. This is the most widely used definition of
treatment resistance; whilst duration of depression is not
a part of the definition, in practice the large majority of
those with a single depressive episode also had chronic
depression (i.e. episode duration of 2 years or more).
Given that there is no widely accepted definition of TRBD,
the same criteria as for TRUD were used, although other
criteria also including mood stabiliser use have more
recently been proposed for TRBD22. General exclusion
criteria were: an organic cause for depression; a systemic
physical illness or neurological condition that affects
cortisol levels; regular use of corticosteroids or other
medication affecting the HPA axis; heavy smoking (>20
cigarettes per day); alcohol dependence or recreational
drug use in the last 6 months; and pregnancy or lactation.
Neither comorbid mental disorders nor being on psy-
chotropic medication were exclusionary criteria, but
both were recorded.
Controls aged 18–75 years were recruited from our
database of volunteers, which included hospital and uni-
versity staff and students and also members of the local
community. Exclusionary criteria for controls included a
personal history of any form of mental disorder; a history
of mental disorder in a first-degree relative; any current
physical or systemic illness; use of any medication likely
to affect the HPA axis; a current Beck Depression
Inventory23 score >10; and a positive urine drug screen.
Controls were matched with patients according to their
age ± 5 years, sex, and Body Mass Index (BMI) ± 5 kg/m2.
Applying the eligibility criteria resulted in three groups:
n= 37 individuals with TRUD, n= 17 individuals with
TRBD, and n= 47 healthy controls. Although the sample
sizes of the three groups were not specifically calculated
for the purpose of the present study, the number of
recruited individuals is similar to previous research on
post-awakening cortisol in individuals with depression6,24.
The research protocol was approved by the local research
ethics committee (London: Camberwell St Giles) and
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written informed consent was obtained from all participants
after receiving a complete description of the study.
Cortisol measurement
Two measures of post-awakening cortisol were of
interest in the present study: (1) total cortisol production
in the morning hours, and (2) the CAR. Participants were
asked to provide six salivary samples in the morning
(upon awakening, and +15, +30, +45, +60, and +90 min
thereafter) over two consecutive days, which could be any
weekday excluding Monday. They were provided with
oral and written instructions, which explained in simple
terms the scientific reasons for undertaking the study and
how the sampling was to be done. Participants were to try
and avoid undertaking any strenuous leisure activities, late
nights, and use of alcohol during the two collection days.
They were not to have anything to eat or drink or brush
their teeth until after the 90min of sampling. Samples
were collected in polypropylene tubes using the passive
drool method. Inpatients were instructed to hand in the
daily samples to a member of staff and outpatients were
provided with an envelope to post the samples back to
the Affective Disorders Unit laboratory after storing in a
refrigerator in the interim. All samples were stored at
−40 °C and cortisol concentrations were determined
using the luminescence assay of ‘Immulite’—Siemens’
automated Immunoassay analyser (www.diagnostic.
siemens.com), as described in Mondelli et al.25. Inter-
and intra-assay variance was <10%.
Statistical analysis
Post-awakening cortisol levels were measured by cal-
culating the areas under the curve with respect to the
ground (AUCg) and with respect to the increase (AUCi)26.
The former is thought to reflect the total cortisol pro-
duction in the morning hours and the latter indicates the
CAR. Compliance was defined as the sample being
recorded as taken within 10 min of the scheduled time. In
those cases, where there were missing values other than at
0 and 90mins, the mean value of the two proximal time
points was inserted. Where either 0 or 90min values were
missing, the AUC was not calculated. We calculated
Pearson’s product–moment coefficients, Spearman
rank correlations, t tests, and Mann–Whitney U tests as
appropriate to identify relevant confounders of cortisol
(i.e. place of collection, day of collection, time of awa-
kening, BMI, smoking status, comorbidities with other
mental disorders, physical illnesses, and the intake of
medication). No significant confounders of cortisol were
found and thus t tests were used for group comparisons
between TRUD and healthy controls, TRBD and healthy
controls, and TRUD vs. TRBD. For non-parametric data,
Mann–Whitney U tests were used. All reported p values
are two-tailed and a correction for multiple comparisons
was applied using the rough false discovery rate27. Data




Demographics of all participants are shown in Table 1.
Our sample mainly consisted of middle-aged adults, with
a female preponderance. Three bipolar and two unipolar
patients had been seen only as outpatients; the rest had
been inpatients. According to the BMI, both patients and
controls were overweight on average. In both patient
groups, comorbidity rates with anxiety disorders were
highest. The large majority of patients were taking med-
ication at the time of assessment, most commonly anti-
depressants and mood stabilisers. In terms of part
treatment history, patients were highly treatment resis-
tant, with mostly around ten failed treatments.
Treatment resistant unipolar depression vs. healthy
controls
In total, 37 patients with TRUD and a mean HAMD
21 score of 23.5 ± 5.5 were recruited into the study. The
median duration of illness since the age of onset was 13
(IQR 19) years. The median duration of the current
depressive episode was 4 (5) years.
Post-awakening cortisol concentrations of patients with
TRUD at each time point are shown in Fig. 1. The averaged
AUCg for the two measurement days was higher in patients
with TRUD compared to controls (1385.6 ± 516.0 nmol/l.
min vs. 1097.7 ± 392.0 nmol/l.min; t= 2.576, df= 64, p=
0.01). The mean AUCi, by contrast, did not differ between
patients and controls (232.6 ± 468.9 nmol/l.min vs. 108.6 ±
448.9 nmol/l.min; t= 1.084, df= 64, p= 0.28). Results did
not change when looking at both assessment days separately
(data not shown, but see Fig. 2).
Treatment-resistant bipolar depression vs. healthy controls
In total, 17 patients with TRBD and a mean HAMD 21
of 23.9 ± 4.5 were recruited into the study. The median
duration of illness since the age of onset was 15 (IQR 13)
years. The median duration of the current depressive
episode was 3 (3) years.
Post-awakening cortisol concentrations in patients with
TRBD at each time point are shown in Fig. 1. The aver-
aged AUCg over the two assessment days was lower in
patients compared to controls, although only by trend
(836.4 (IQR 336.6) nmol/l.min vs. 1106.2 (619.1) nmol/l.
min; z=−1.796, p= 0.07). The AUCi was not sig-
nificantly different between patients and controls
(−88.8 ± 387.2 nmol/l.min vs. 108.6 ± 448.9 nmol/l.min;
t=−1.460, df= 51, p= 0.15). When looking at both
assessment days individually, it became clear that the
trend in the averaged AUCg was driven by a significant
Markopoulou et al. Translational Psychiatry          (2021) 11:244 Page 3 of 8
group difference on day 1 (patients: 852.6 ± 322.5 nmol/l.
min vs. controls: 1126.0 ± 434.9 nmol/l.min; t=−2.165,
df= 56, p= 0.03), whereas patients and controls did not
differ on day 2 (960.0 (779.6) nmol/l.min vs. 1060.4
(682.1) nmol/l.min; z=−0.244, p= 0.80; see also Fig. 2).
Similarly, groups differed in their AUCi on day 1 (patients:
−209.2 (434.4) vs. controls: 184.5 (652.1); z=−2.017,
p= 0.04), but not on day 2 (53.2 ± 698 vs. 74.9 ± 552.2;
t=−0.130, df= 55, p= 0.90).
Treatment-resistant unipolar depression vs. treatment-
resistant bipolar depression
Post-awakening cortisol concentrations in both patient
groups are displayed in Fig. 1. The averaged AUCg was
higher in patients with TRUD when compared to patients
with TRBD (1385.6 ± 516.0 nmol/l.min vs. 902.2 ±
304.3 nmol/l.min; t= 3.216, df= 39, p= 0.003), and the
same was true regarding the AUCi (232.6 ± 468.9 nmol/l.
min vs. −88.8 ± 387.2 nmol/l.min; t= 2.201, df= 39, p=
0.03). Again, these differences seemed to be more
apparent on day 1 (AUCg: 1392.2 ± 559.4 nmol/l.min vs.
852.6 ± 322.5 nmol/l.min; t= 3.353, df= 43, p= 0.002;
AUCi: 77.2 (861.0) nmol/l.min vs. −209.2 (434.4) nmol/l.
min; z= 2.023, p= 0.04) rather than on day 2 (AUCg:
1339.5 ± 550.6 nmol/l.min vs. 1101.5 ± 527.4 nmol/l.min;
t= 1.461, df= 47, p= 0.15; AUCi: 307.9 (529.6) nmol/l.
min vs. 53.2 (628.0) nmol/l.min; t= 1.501, df= 47,
p= 0.14).
Discussion
The main finding of this study is that patients with
TRUD had higher total cortisol concentrations in the
morning hours when compared to healthy controls. In
contrast, patients with TRBD exhibited a change in the
opposite direction, i.e. a tendency towards diminished
post-awakening cortisol concentrations. There was a clear
difference in post-awakening cortisol when TRUD and
TRBD were directly compared.
To the best of our knowledge, this is the first time that
post-awakening cortisol concentrations were measured
in clearly defined TRUD, although given that in the
McAllister-Williams et al.17 study all patients had to use
serotonergic antidepressants upon study entry, their
sample of patients with a treatment resistant major
depressive episode is likely to contain a high proportion of
patients with TRUD. Our finding of relatively elevated
post-awakening cortisol concentrations contradicts the
null-finding by McAllister-Williams et al.17, who may
have also included cases with TRBD, while being in line
with previous research confined to patients with unipolar
depression24,28. Notably, we found total cortisol produc-
tion during the morning hours rather than the CAR to
distinguish patients with TRUD from healthy controls.
This dissociation between the AUCg and AUCi is in line
with findings from the Netherlands Study of Depression
and Anxiety28, and may mean that (morning) HPA
activity rather than reactivity is abnormal in TRUD. This
notion is compatible with meta-analytical evidence failing
to support altered cortisol responses in depression both
upon pharmacological stimulation with exogenous
corticotropin-releasing hormone (CRH) or adrenocorti-
cotropic hormone (ACTH)4, and upon being exposed to
acute psychosocial stress29. Notably, Vreeburg et al.28
found the AUCg elevated in remitted patients as well,
which may mean that elevated total morning cortisol is a
trait-like marker of unipolar depression rather than being
specifically linked to treatment resistance.
Contrary to TRUD, we found a tendency in patients with
TRBD to show attenuated total cortisol concentrations in
Table 1 Characteristics of patients with treatment-
resistant unipolar depression, treatment-resistant bipolar










Age (years) 52 ± 13 52 ± 10 50 ± 16
Sex
Male 9 (24%) 7 (41%) 21 (45%)
Female 28 (76%) 10 (59%) 26 (55%)
BMI (kg/m²) 30 ± 7.3 27.5 ± 6.2 26.3 ± 4.5
Duration of current episode
(years), median (IQR)
4 (5) 3 (3) −
Total illness duration (years),
median (IQR)
13 (19) 15 (13)
Previous treatment failures,
median (IQR)
Antidepressants 6 (3) 4 (4)
Mood stabilisers 2 (1) 3 (2)
Antipsychotics 1 (2) 1 (1)
Augmenters 0 (1) 0 (1)
Anxiolytics/hypnotics 1 (1) 0 (1)
All medication 11 (7) 9 (7)
Previous ECTa 18/30 (60%) 6/15 (40%)
Comorbidity −
Anxiety disorder 17 (46%) 5 (29%)
Eating disorders 2 (5%) 1 (6%)
Personality disorders 4 (11%) 1 (6%)
Medication −
Antipsychotics 12 (32%) 1 (6%)
Benzodiazepines/hypnotics 18 (49%) 4 (24%)
One mood stabilisers 16 (43%) 4 (24%)
≥ 2 mood stabilisers 5 (14%) 10 (59%)
SNRI 12 (32%) 3 (18%)
SSRI 6 (16%) 0 (0%)
Tricyclics 8 (22%) 1 (6%)
Other antidepressants 12 (32%) 2 (12%)
Thyroid hormones 8 (22%) 3 (18%)
BMI body mass index, HC healthy controls, SNRI serotonin noradrenaline
reuptake inhibitors, SSRI selective serotonin reuptake inhibitors, TRBD treatment
resistant bipolar depression, TRUD treatment resistant unipolar depression
aData not available for all patients.
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the morning hours. This is the first time that post-
awakening concentrations were measured in patients with
clearly defined TRBD. In fact, barely any research has
investigated post-awakening cortisol in patients with
bipolar disorder generally and bipolar depression in par-
ticular—regardless of treatment resistance6. This means
that it remains unclear to what extent the present findings
are applicable to TRBD only or to patients with bipolar
Fig. 1 Post-awakening cortisol by group. Graph of post-awakening cortisol concentrations in patients with treatment-resistant unipolar depression
(n= 37), treatment-resistant bipolar depression (n= 17), and in healthy controls (n= 47); means and standard errors of means, averaged across two
consecutive days.
Fig. 2 Area under the curve of post-awakening cortisol by group and by day. Bar charts of post-awakening cortisol calculated as the area under
the curve in patients with treatment-resistant unipolar depression (n= 37), treatment-resistant bipolar depression (n= 17), and in healthy controls
(n= 47); means and standard errors of means on day 1, day 2, and averaged across both days (from left to right); see manuscript for results of
statistical comparison between groups.
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disorder in general. Of the three previous studies that
have measured this parameter, one found higher9 and two
normal7,8 post-awakening cortisol levels in bipolar
depression. Notably, all of these studies measured cortisol
on one day only, whereas we averaged it over two days.
This latter protocol is in line with recently published
guidelines, which recommend that CAR data are obtained
on at least 2 days due to their high susceptibility to the
influence of state variables30. In addition, the study by
Jabben et al.9 used a self-report screen for bipolar spec-
trum rather than a formal clinical diagnosis, and is thus
likely to contain many patients not meeting full criteria
for bipolar disorder.
It is noteworthy, however, that our finding was driven
by significant differences between TRBD and healthy
controls on assessment day 1, while the primary analyses
(averaged analyses) only revealed a trend. Novelty effects
could have driven the observed differences between
patients and controls on the first assessment day, while
preventing us from detecting significant differences on
day 2, when participants were more familiar with the
protocol. Although not specifically studied in relation to
post-cortisol awakening cortisol concentrations, the lit-
erature on exposure to repeated acute psychosocial stress
in the laboratory suggests novelty to be an essential ele-
ment underlying HPA axis responses31. In this context,
higher trait novelty seeking—which is more prevalent in
bipolar disorder when compared to both unipolar dis-
order and healthy individuals32—might have amplified the
herein found difference on the first assessment day by
moderating post-awakening cortisol output. This would
fit in well with studies showing that healthy individuals
scoring high on novelty seeking demonstrated relatively
diminished cortisol reactivity to different types of stimuli
challenging the HPA axis33,34. However, as we did not
assess temperament in the present study, this notion
remains purely speculative. Also, the small size of the
TRBD group somewhat limits the interpretation of this
finding, and more research in this highly selected group of
patients is warranted in the future.
We found opposite post-awakening cortisol patterns in
TRUD and TRBD: whereas our TRUD group exhibited a
similar cortisol pattern to that of the healthy controls, the
TRBD group appeared to be characterised by a more rapid
decrease in cortisol starting 30min after awakening. This
finding contradicts a previous study that did not find any
differences between depressed patients with vs. without a
history of a hypomanic episode35. The possible inclusion
of bipolar spectrum disorder rather than ICD-10 or DSM
bipolar disorder and the use of only one day of cortisol
measurement may account for this discrepancy. Further-
more, Becking et al.35 included individuals with less severe
forms of depression. Indeed, it would be highly interesting
for future research to investigate whether the observed
differences only emerge in specific subtypes of patients
with (treatment-resistant) depression and whether there is
a dose-response relationship between the number of
depressive episodes experienced and the degree of altera-
tions in post-awakening cortisol.
A number of limitations need to be acknowledged. First,
our sample was recruited from a specialist service of
treatment-resistant patients and so our results may not be
encountered in other settings that attract patients with less
severe depressive symptoms. Second, given that there is no
widely accepted definition of TRBD, the same criteria as for
TRUD were used in the present study. It might be argued
that failure to respond to antidepressant medication in
bipolar depression may not represent true treatment resis-
tance, but rather a ‘paradigm failure’ in treatment3,36 and
thus pseudo-resistance instead. Against this, whilst we
defined treatment resistance according to failed anti-
depressant treatment in order to standardise across all
patients, in fact the patients with TRBD in this study had
previously also received adequate treatment trials with an
average of four non-antipsychotic or antipsychotic mood
stabilisers in addition to antidepressants. This represents a
similar level of resistance to that seen in clinical studies of
TRBD37 and to recent suggestions for defining TRBD that
involve two failed mood stabiliser treatments22, and con-
firms the high degree of treatment resistance to targeted
treatments for bipolar depression in the studied group.
Moreover, the use of antidepressants in bipolar depression
remains a commonly used real-world treatment option38.
Third, using participants on medication is a limitation, given
that many psychotropic medications affect the HPA axis. For
instance, Sarubin et al.39 recently showed that both quetia-
pine and escitalopram exerted an effect on depressed
patients’ HPA functioning when administered over 5 weeks.
More specifically, quetiapine was shown to mildly dampen
cortisol levels, whereas only a transient rise in cortisol was
observed in the escitalopram group. Similarly, mood stabi-
lisers, such as lithium, seem to affect the HPA axis in the
long-term, such as that current intake was linked to normal
or elevated cortisol concentrations in patients with bipolar
disorder40. However, it is unlikely that medication accounted
for the differences found between TRUD and TRBD, since
our two samples were taking similar medications and to a
similar extent, medication intake was found statistically
unrelated to cortisol concentrations, and, if anything,
opposite findings would have been expected based on the
available literature. Fourth, the CAR has been linked to
certain sleep-related variables, namely sleep duration and
waking time, albeit very inconsistently41. While the design of
the present study did not allow us to obtain polysomno-
graphic sleep measures, awakening time was not related to
post-awakening cortisol. Notwithstanding this, it would be
interesting for future studies to obtain objective and/or
subjective measures of sleep, and to study these in relation to
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depression and the CAR. We further encourage any studies
interested in the CAR to adhere to the recently published
expert consensus guidelines, which provide an excellent
review of the methodological challenges pertaining to its
measurement30.
The tendency towards low post-awakening cortisol
concentrations in TRBD may have important clinical
implications. Provided this is replicated in future studies,
it would subsequently be useful to clarify whether hypo-
cortisolaemia in TRBD is a product of treatment resis-
tance, perhaps induced by the chronicity of the illness, or
whether hypocortisolaemia instead contributes to treat-
ment resistance. In unipolar depression, evidence is in fact
accumulating for the latter, that is, for HPA axis
abnormalities to be related to worse outcomes after first-
line treatments42,43. If this proves true in bipolar depres-
sion as well, novel treatment strategies may be indicated
for this patient group. In relation to pharmacological
treatment, methods to increase HPA axis activity may be
beneficial in TRBD as opposed to the existing strategies to
decrease HPA activity, which are often used in unipolar
depression, including the known effects of standard
antidepressants and specific strategies to lower HPA
activity such as ketoconazole or metyrapone44. Notably,
the latter may only prove useful in a subgroup of patients
with pre-treatment HPA abnormalities, as suggested by
McAllister-Williams et al.17. The potential beneficial
effects of increasing HPA axis activity may mirror the
benefits seen in other conditions that may overlap with
atypical depression, such as chronic fatigue syndrome45. It
may thus be that post-awakening cortisol levels could not
only serve as a biomarker that allows differentiating
between unipolar and bipolar depression, but also an
indicative biomarker to optimise choice of therapy.
Bearing in mind the complexities attached to its mea-
surement30, further research is warranted to replicate our
findings and to evaluate its diagnostic and prognostic
potential against other biomarkers.
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